Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

Red blood cell transfusion independence (RBC-TI) is an important goal in treating lower-risk myelodysplastic syndromes with ring sideroblasts. In the phase 3 MEDALIST study, RBC-TI of ≥ 8 weeks was achieved by significantly more luspatercept- versus placebo-treated patients in the first 24 weeks of...

Descripción completa

Detalles Bibliográficos
Autores principales: Germing, Ulrich, Fenaux, Pierre, Platzbecker, Uwe, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Yucel, Aylin, Tang, Derek, Fabre, Shannon, Zhang, George, Zoffoli, Roberto, Ha, Xianwei, Miteva, Dimana, Hughes, Christina, Komrokji, Rami S., Zeidan, Amer M., Garcia-Manero, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889415/
https://www.ncbi.nlm.nih.gov/pubmed/36635381
http://dx.doi.org/10.1007/s00277-022-05071-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889415/
https://www.ncbi.nlm.nih.gov/pubmed/36635381
http://dx.doi.org/10.1007/s00277-022-05071-8

Ejemplares similares